New Version Available!
Users are strongly advised to only use the latest, up-to-date versions of DIANA-Tools and Databases.
Please follow this link to navigate to the latest database version.
Please follow this link to navigate to the latest database version.
Please cite:
I. S. Vlachos, M. D. Paraskevopoulou, D. Karagkouni, G. Georgakilas, T. Vergoulis, I. Kanellos, I-L. Anastasopoulos, S. Maniou, K. Karathanou, D. Kalfakakou, A. Fevgas, T. Dalamagas and A. G. Hatzigeorgiou. DIANA-TarBase v7.0: indexing more than half a million experimentally supported miRNA:mRNA interactions. Nucl. Acids Res. (2014)
Data Download:
|
||||||||
Related Pathways
Publication year
Prediction score
Filters
Selected:
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Species: -
Regulation: -
Validation: -
Validated: -
Sources: -
Methods: -
Remove all 
Species
Method Type
Method
Regulation type
Validation type
Validated as
Source
Publication year
Prediction score
Loading... |
| Wait until the result set is completed... |
Gene name
miRNA name
Methods
Pred.Score
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr18:21042138-21042159 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:87398662-87398682 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:110194654-110194682 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:46625517-46625544 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:76210281-76210300 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:113715013-113715034 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:142311448-142311469 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr3:142422642-142422668 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr3:142311448-142311469 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:39032137-39032156 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:98579569-98579590 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:133955573-133955592 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:37099601-37099629 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:143305933-143305954 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:4488878-4488897 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr12:4488878-4488897 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr12:4488878-4488897 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:58005035-58005056 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:172400564-172400589 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr18:56691775-56691793 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:95166200-95166226 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:222633274-222633298 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:197474279-197474301 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr2:197474279-197474301 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:8086830-8086855 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:8086830-8086855 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:8086830-8086855 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:8086830-8086855 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:8086830-8086855 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:8086830-8086855 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:122894045-122894066 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr4:122894045-122894066 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:79324961-79324976 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:132372555-132372573 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:38479425-38479453 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:102826682-102826706 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr8:102828167-102828187 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:123910536-123910559 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr18:42081493-42081515 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr18:42081493-42081515 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:75644221-75644249 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:112973051-112973073 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr12:112973051-112973073 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:37480438-37480456 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:30367346-30367372 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:87770960-87770985 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:155335401-155335422 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:113940719-113940739 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:73790541-73790561 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:69271105-69271118 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:77284959-77284987 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:41957216-41957229 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SCFD1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:30653539-30653566 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CEP57L1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:109162935-109162956 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FDFT1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:11831629-11831657 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RPL6 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:112405957-112405975 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FNDC3A (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr13:49209446-49209467 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr13:49209446-49209467 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr13:49209446-49209467 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr13:49209446-49209467 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr13:49209446-49209467 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CACYBP (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:175010653-175010676 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FANCD2 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:10098767-10098785 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TRAM1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:70574616-70574636 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
C6orf48 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:31839566-31839585 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KLF6 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:3777945-3777962 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PRUNE (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:151034486-151034509 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DECR1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:90005639-90005667 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PER3 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:7785456-7785481 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FNIP1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:131641720-131641740 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr5:131641720-131641740 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CPEB3 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:92049832-92049856 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DZIP1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr13:95584875-95584896 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
EPB41 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:29117518-29117536 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TMEM165 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:55411685-55411712 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FAM84B (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr8:126552935-126552963 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CYB5R3 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:42618923-42618949 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KMT2C (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:152252055-152252083 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:152181270-152181298 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SLIT3 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:168665526-168665554 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TRPM7 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr15:50609887-50609908 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
WDR59 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:74949719-74949745 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
BTBD7 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:93240291-93240312 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 4 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FAT1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:186603632-186603655 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TNRC6A (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr16:24789588-24789616 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr16:24823933-24823952 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
chr16:24825274-24825300 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr16:24823933-24823952 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CAST (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:96773719-96773731 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MGEA5 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:101785447-101785468 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
LAMP2 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:120437546-120437567 (UNKNOWN)
B cell lines infected by KSHV virus. AGO Immunoprecipitation using anti-Argonaute 2A8. 3 replicates available
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
AKIRIN1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:39004044-39004071 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr1:39004044-39004071 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SCO1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:10680569-10680589 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SLC12A2 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:128187927-128187946 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KLHL15 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:23984632-23984658 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SREK1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:66181181-66181209 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SFPQ (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr1:35191434-35191448 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RNMT (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr18:13763155-13763174 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr18:13763155-13763174 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr18:13763155-13763174 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SLC11A2 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:50986703-50986723 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr12:50986703-50986723 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr12:50986703-50986723 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MAPK8 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr10:48435387-48435398 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
NUP107 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr12:68742606-68742626 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZNF264 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:57215662-57215682 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CHORDC1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:90214058-90214082 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RPS4X (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chrX:72272647-72272666 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chrX:72272647-72272666 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
SPECC1L (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:24411661-24411682 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
KIAA1109 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:122238118-122238135 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MED12L (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:151434881-151434894 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RHEB (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:151466765-151466784 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
MIEF1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:39514731-39514754 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
DHX40 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:59570550-59570576 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RCOR1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr14:102727641-102727668 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RBFOX2 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr22:35742340-35742364 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
EFTUD2 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr17:44880567-44880577 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
RNF14 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr5:141984884-141984905 (UNKNOWN)
Primary effusion lymphoma cell line BC-1
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
GPANK1 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr6:31664070-31664091 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
FAT3 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr11:92352322-92352350 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
HLTF (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:149075910-149075922 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
TBC1D9 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr4:140621241-140621261 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
PIK3CB (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:138742650-138742669 (UNKNOWN)
Pancreatic Islets. AGO2 immunoprecipitation using HITS-CLIP antibody: Argonaute antibody 2A9
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
INHBB (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr2:120351446-120351469 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Santa Cruz).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CALM3 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr19:46610722-46610750 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Abnova, antibody catalog #: H00027161-M01).Treatment protocol: treated with 1 mM sodium arsenite for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
ZNF12 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr7:6690573-6690596 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 20 μg/mL emetine for 60 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:6690184-6690193 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:6690184-6690193 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
Location
Method
Result
Regulation
Valid. type
Source
chr7:6690184-6690193 (UNKNOWN)
LCL-BACD3 lymphoblastoid cells infected by EBV B95-8 BACmid. LCL-BAC-D1 cells were generated from the same donor as LCL-BAC and are mutationally inactivated for miR-BHRF1-3 expression. antibody: Anti-Ago2 (clone 9E8).
PAR-CLIP
POSITIVE
DIRECT
Tarbase 7.0
CEP97 (hsa)
hsa-miR-190b
-
Publication
Methods
Tissue
Cell line
Tested cell line
Exp. condition
Location
Method
Result
Regulation
Valid. type
Source
chr3:101767797-101767823 (UNKNOWN)
AGO2 immunoprecipitation (antibody manufacturer: Sigma).Treatment protocol: treated with 1 μM hippuristanol for 30 minutes.
HITS-CLIP
POSITIVE
DIRECT
Tarbase 7.0